ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-07 08:00:00,2025-10-07T08:00:00-04:00,2025-10-07,"Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses","Studies presented at #Academy25 reveal that ACUVUE OASYS MAX 1-Day for ASTIGMATISM outperformed Dailies Total1® for Astigmatism in patient reported outcomes related to vision and comfort. Research highlights that the latest ACUVUE contact lens innovation OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM broadens the range of patients who can benefit from daily disposable multifocal contact lenses, especially those with astigmatism.",prnewswire.com,https://www.prnewswire.com/news-releases/johnson--johnson-unveils-new-data-demonstrating-superior-clarity-of-vision-and-comfort-of-acuvue-oasys-max-1-day-for-astigmatism-and-multifocal-for-astigmatism-contact-lenses-302576236.html,https://images.financialmodelingprep.com/news/johnson-johnson-unveils-new-data-demonstrating-superior-clarity-of-20251007.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-07 08:05:00,2025-10-07T08:05:00-04:00,2025-10-07,Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill,"Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated with the highest dose achieving endoscopic improvement at Week 12 in the Phase 2b ANTHEM-UC study These data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor as a potential new option for people with moderately to severely active ulcerative colitis SPRING HOUSE, Pa. , Oct. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC).",prnewswire.com,https://www.prnewswire.com/news-releases/icotrokinra-data-in-ulcerative-colitis-show-potential-for-a-standout-combination-of-therapeutic-benefit-and-a-favorable-safety-profile-in-once-daily-pill-302576329.html,https://images.financialmodelingprep.com/news/icotrokinra-data-in-ulcerative-colitis-show-potential-for-a-20251007.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-07 08:05:00,2025-10-07T08:05:00-04:00,2025-10-07,TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis,"Patients treated with subcutaneous TREMFYA® achieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study Clinical and endoscopic outcomes were demonstrated across both biologic-naïve and biologic-refractory sub-groups TREMFYA ®  is the only IL-23 inhibitor with a fully subcutaneous regimen, following recent FDA approval of SC induction in adults with ulcerative colitis SPRING HOUSE, Pa. , Oct. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely active ulcerative colitis (UC).",prnewswire.com,https://www.prnewswire.com/news-releases/tremfya-guselkumab-is-first-and-only-il-23-inhibitor-to-demonstrate-sustained-clinical-and-endoscopic-outcomes-with-a-fully-subcutaneous-regimen-through-48-weeks-in-ulcerative-colitis-302576330.html,https://images.financialmodelingprep.com/news/tremfya-guselkumab-is-first-and-only-il23-inhibitor-to-20251007.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-07 10:50:31,2025-10-07T10:50:31-04:00,2025-10-07,Johnson & Johnson ordered to pay $966 million after jury finds company liable in talc cancer case,"A Los Angeles jury late on Monday ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest lawsuit alleging its baby powder products cause cancer.",reuters.com,https://www.reuters.com/legal/litigation/johnson-johnson-ordered-pay-966-million-after-jury-finds-company-liable-talc-2025-10-07/,https://images.financialmodelingprep.com/news/johnson-johnson-ordered-to-pay-966-million-after-jury-20251007.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-07 16:19:00,2025-10-07T16:19:00-04:00,2025-10-07,LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict,"LOS ANGELES--(BUSINESS WIRE)--A Los Angeles County jury has returned damages totaling $966 million, including $950 million in punitive damages, to the family of Mae Moore, who died of mesothelioma in 2021 after using Johnson & Johnson's iconic baby powder. Lawyers for the family say this is the largest verdict ever against Johnson & Johnson in a mesothelioma case linked to talc products. Ms. Moore, the wife of a pastor and a mother of three, regularly used Johnson & Johnson's baby p.",businesswire.com,https://www.businesswire.com/news/home/20251007971192/en/LA-County-Jury-Hits-Johnson-Johnson-with-Nearly-1-Billion-Verdict/,https://images.financialmodelingprep.com/news/la-county-jury-hits-johnson-johnson-with-nearly-1-billion-20251007.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-07 20:58:00,2025-10-07T20:58:00-04:00,2025-10-07,Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfolio,"It's impossible to predict with certainty whether a recession is coming, but certain developments sure make it more likely. President Donald Trump's tariff policies could lead to increased prices and plunge the economy into a downturn.",fool.com,https://www.fool.com/investing/2025/10/07/worried-about-a-recession-2-stocks-to-buy-now-to-p/,https://images.financialmodelingprep.com/news/worried-about-a-recession-2-stocks-to-buy-now-20251007.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-08 02:42:08,2025-10-08T02:42:08-04:00,2025-10-08,Johnson & Johnson ordered to pay $966 million in talc cancer case after jury finds company liable,"A Los Angeles jury ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest trial alleging its talc products cause cancer.",nypost.com,https://nypost.com/2025/10/08/business/johnson-and-johnson-ordered-to-pay-966-million-in-mae-moore-baby-powder-cancer-lawsuit/,https://images.financialmodelingprep.com/news/johnson-johnson-ordered-to-pay-966-million-in-talc-cancer-20251008.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-08 07:17:01,2025-10-08T07:17:01-04:00,2025-10-08,Why AbbVie and Johnson & Johnson Could Outperform Pfizer,Pfizer Inc. NYSE: PFE made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of around $23.61 on Sept.,marketbeat.com,https://www.marketbeat.com/stock-ideas/why-abbvie-and-johnson-and-johnson-could-outperform-pfizer/,https://images.financialmodelingprep.com/news/why-abbvie-and-johnson-johnson-could-outperform-pfizer-20251008.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-08 09:46:10,2025-10-08T09:46:10-04:00,2025-10-08,3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal,"Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.",zacks.com,https://www.zacks.com/stock/news/2764279/3-large-drug-stocks-to-watch-as-industry-recovers-after-pfe-trump-deal?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2764279,https://images.financialmodelingprep.com/news/3-large-drug-stocks-to-watch-as-industry-recovers-20251008.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-08 09:50:19,2025-10-08T09:50:19-04:00,2025-10-08,These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar,Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.,zacks.com,https://www.zacks.com/stock/news/2764298/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_earnings_esp-2764298,https://images.financialmodelingprep.com/news/these-2-medical-stocks-could-beat-earnings-why-they-20251008.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-08 13:11:16,2025-10-08T13:11:16-04:00,2025-10-08,Why Johnson & Johnson (JNJ) is Poised to Beat Earnings Estimates Again,Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,zacks.com,https://www.zacks.com/stock/news/2764763/why-johnson-johnson-jnj-is-poised-to-beat-earnings-estimates-again?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_7-2764763,https://images.financialmodelingprep.com/news/why-johnson-johnson-jnj-is-poised-to-beat-earnings-20251008.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-08 15:11:26,2025-10-08T15:11:26-04:00,2025-10-08,Goldman Sachs expects another quarter of outperformance from J&J in Q3,"Johnson & Johnson (NYSE:JNJ)'s strong year-to-date performance is likely to continue when the healthcare giant reports third quarter earnings on October 14, according to analysts at Goldman Sachs. The firm wrote in a note to clients that the stock's 31% gain this year, which is more than double the S&P 500's 14% rise, reflects “impressive execution across the Innovative Medicines segment,” which has driven sales and earnings estimates higher relative to peers.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1079975,https://images.financialmodelingprep.com/news/goldman-sachs-expects-another-quarter-of-outperformance-from-jj-20251008.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-09 10:01:16,2025-10-09T10:01:16-04:00,2025-10-09,Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It,"Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",zacks.com,https://www.zacks.com/stock/news/2765226/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2765226,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-is-a-trending-stock-facts-to-20251009.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-09 10:15:33,2025-10-09T10:15:33-04:00,2025-10-09,Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings,"Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",zacks.com,https://www.zacks.com/stock/news/2765283/wall-street-s-insights-into-key-metrics-ahead-of-johnson-johnson-jnj-q3-earnings?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2765283,https://images.financialmodelingprep.com/news/wall-streets-insights-into-key-metrics-ahead-of-johnson-20251009.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-09 16:24:00,2025-10-09T16:24:00-04:00,2025-10-09,Johnson & Johnson to Participate in the UBS Global Healthcare Conference,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the UBS Global Healthcare Conference on Tuesday, November 11th, 2025. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximat.",businesswire.com,https://www.businesswire.com/news/home/20251009718064/en/Johnson-Johnson-to-Participate-in-the-UBS-Global-Healthcare-Conference/,https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-ubs-global-healthcare-20251009.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 02:42:46,2025-10-10T02:42:46-04:00,2025-10-10,Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts,"Johnson & Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.",benzinga.com,https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48141839/johnson-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts-3,https://images.financialmodelingprep.com/news/johnson-johnson-gears-up-for-q3-print-here-are-the-20251010.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 07:30:00,2025-10-10T07:30:00-04:00,2025-10-10,Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress,"17 abstracts from across the Company's portfolio and pipeline highlight new clinical and real-world data on major depressive disorder and treatment-resistant depression New post-hoc analysis of CAPLYTA® (lumateperone) Phase 3 data evaluates the impact on sexual function in MDD, reinforcing potential to reset treatment expectations European Union and United Kingdom sub-group analyses of Phase 3 data evaluate efficacy of adjunctive seltorexant compared to adjunctive quetiapine XR in MDD with insomnia symptoms New data from post-hoc analysis of ESCAPE-TRD explores association of patient characteristics and remission with SPRAVATO® (esketamine) versus quetiapine XR in treatment-resistant depression TITUSVILLE, N.J. , Oct. 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 17 abstracts featuring new clinical and real-world data will be presented at the annual European College of Neuropsychopharmacology (ECNP) Congress, taking place October 11-14 in Amsterdam, The Netherlands.",prnewswire.com,https://www.prnewswire.com/news-releases/johnson--johnson-to-highlight-breadth-of-its-major-depressive-disorder-portfolio-at-2025-ecnp-congress-302580374.html,https://images.financialmodelingprep.com/news/johnson-johnson-to-highlight-breadth-of-its-major-depressive-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 07:48:43,2025-10-10T07:48:43-04:00,2025-10-10,Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced,"Johnson & Johnson is currently overvalued, with limited upside and mid-to-high single-digit long-term return potential amid ongoing sector risks. Despite solid recent earnings and raised guidance, JNJ faces headwinds from potential tariffs, drug price pressures, and declining Stelara sales. Management projects strong oncology growth, but analyst consensus remains cautious, forecasting more modest earnings growth than company targets.",seekingalpha.com,https://seekingalpha.com/article/4829076-johnson-and-johnson-safe-haven-quietly-becoming-overpriced,https://images.financialmodelingprep.com/news/johnson-johnson-a-safe-haven-thats-quietly-becoming-a-bit-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 11:13:00,2025-10-10T11:13:00-04:00,2025-10-10,Johnson & Johnson in Talks to Buy Protagonist Therapeutics,The two companies are already codeveloping a treatment for ulcerative colitis.,wsj.com,https://www.wsj.com/health/pharma/johnson-johnson-in-talks-to-buy-protagonist-therapeutics-38e0b69d,https://images.financialmodelingprep.com/news/johnson-johnson-in-talks-to-buy-protagonist-therapeutics-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 11:25:40,2025-10-10T11:25:40-04:00,2025-10-10,"Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports","Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-talks-acquire-protagonist-therapeutics-wsj-reports-2025-10-10/,https://images.financialmodelingprep.com/news/johnson-johnson-in-talks-to-acquire-protagonist-therapeutics-wsj-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 13:06:05,2025-10-10T13:06:05-04:00,2025-10-10,Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report,Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).,benzinga.com,https://www.benzinga.com/m-a/25/10/48155373/johnson-johnson-in-talks-to-acquire-protagonist-therapeutics-report,https://images.financialmodelingprep.com/news/johnson-johnson-in-talks-to-acquire-protagonist-therapeutics-report-20251010.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 13:10:58,2025-10-10T13:10:58-04:00,2025-10-10,Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know,"J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.",zacks.com,https://www.zacks.com/stock/news/2766512/buying-j-j-stock-ahead-of-q3-earnings-here-s-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2766512,https://images.financialmodelingprep.com/news/buying-jj-stock-ahead-of-q3-earnings-heres-what-you-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 13:21:26,2025-10-10T13:21:26-04:00,2025-10-10,RTW Investments' Rod Wong: Expect more deals in biotech space,"Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the sector, and much more.",youtube.com,https://www.youtube.com/watch?v=wM_roCJcbKQ,https://images.financialmodelingprep.com/news/rtw-investments-rod-wong-expect-more-deals-in-biotech-space-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 16:20:00,2025-10-10T16:20:00-04:00,2025-10-10,Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company established pursuant to the laws of the Island of Nevis to purchase up to 500,000 shares of Johnson & Johnson common stock at a price of $145.00 per share in cash. Tutanota's offer price of $145.00 per share was well below the closing price of Johnson & Johnson common stock on September 26, 20.",businesswire.com,https://www.businesswire.com/news/home/20251010467484/en/Johnson-Johnson-recommends-shareholders-reject-%E2%80%9Cmini-tender%E2%80%9D-offer-by-Tutanota/,https://images.financialmodelingprep.com/news/johnson-johnson-recommends-shareholders-reject-minitender-offer-by-tutanota-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 18:36:02,2025-10-10T18:36:02-04:00,2025-10-10,"US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy",The U.S. Food and Drug Administration on Friday approved labeling changes for Johnson & Johnson and its partner Legend Biotech's blood cancer therapy to include a boxed warning for a potentially fatal gastrointestinal condition.,reuters.com,https://www.reuters.com/legal/litigation/us-fda-adds-boxed-warning-jj-legend-biotechs-cancer-therapy-2025-10-10/,https://images.financialmodelingprep.com/news/us-fda-adds-boxed-warning-to-jj-legend-biotechs-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-10 22:11:04,2025-10-10T22:11:04-04:00,2025-10-10,"3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR","Resurfaced tensions between the U.S. and China caught the market off guard in Friday's trading session, with the S&P 500 and Nasdaq falling over 2% on news that President Trump plans to impose an additional 100% tariff on Chinese goods starting November 1st.",zacks.com,https://www.zacks.com/stock/news/2766735/3-defensive-stocks-to-watch-as-trade-tensions-resurface-gild-jnj-kr?cid=CS-STOCKNEWSAPI-FT-stocks_in_the_news-2766735,https://images.financialmodelingprep.com/news/3-defensive-stocks-to-watch-as-trade-tensions-resurface-20251010.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-12 06:57:44,2025-10-12T06:57:44-04:00,2025-10-12,Wall Street Week Ahead,Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.,seekingalpha.com,https://seekingalpha.com/article/4829366-wall-street-week-ahead,https://images.financialmodelingprep.com/news/wall-street-week-ahead-20251012.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-12 09:00:00,2025-10-12T09:00:00-04:00,2025-10-12,Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make,"Johnson & Johnson (JNJ) is rumored to be in talks to acquire Protagonist Therapeutics (PTGX), following significant buyout speculation and a 30% PTGX stock surge. PTGX's value is underpinned by its oral immunology drug icotrokinra and blockbuster potential of rusfertide for polycythemia vera, both with strong partnership structures. A JNJ acquisition could save milestone payments, secure future royalties, and add derisked, late-stage assets to JNJ's portfolio, supporting long-term growth.",seekingalpha.com,https://seekingalpha.com/article/4829332-johnson-and-johnson-to-acquire-protagonist-itd-be-good-deal-to-make,https://images.financialmodelingprep.com/news/johnson-johnson-to-acquire-protagonist-itd-be-a-good-deal-20251012.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-12 15:14:54,2025-10-12T15:14:54-04:00,2025-10-12,Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal,"Douglas Lane & Associates, LLC disclosed a purchase of 34,948 shares of Johnson & Johnson (JNJ -0.24%) in an SEC filing on Friday, representing an estimated $6 million transaction based on average prices during the third quarter.",fool.com,https://www.fool.com/coverage/filings/2025/10/12/douglas-lane-adds-usd6-million-in-j-and-j-stock-ahead-of-earnings-and-possible-biotech-deal/,https://images.financialmodelingprep.com/news/douglas-lane-adds-6-million-in-jj-stock-ahead-of-20251012.png
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-13 09:21:05,2025-10-13T09:21:05-04:00,2025-10-13,Is J&J's MedTech Segment Set for Another Quarter of Growth?,"J&J's MedTech sales are gaining traction in Cardiovascular, Surgery, and Vision, even as China???s VBP program continues to weigh on growth.",zacks.com,https://www.zacks.com/stock/news/2767192/is-j-j-s-medtech-segment-set-for-another-quarter-of-growth?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2767192,https://images.financialmodelingprep.com/news/is-jjs-medtech-segment-set-for-another-quarter-of-20251013.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-13 12:27:44,2025-10-13T12:27:44-04:00,2025-10-13,"Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch",Health care giant Johnson & Johnson (NYSE:JNJ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.,benzinga.com,https://www.benzinga.com/trading-ideas/previews/25/10/48181033/johnson-johnson-q3-preview-with-stock-near-all-time-highs-heres-what-to-watch,https://images.financialmodelingprep.com/news/johnson-johnson-q3-preview-with-stock-near-alltime-highs-20251013.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-13 18:47:00,2025-10-13T18:47:00-04:00,2025-10-13,"Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing","Cyndeo Wealth Partners, LLC purchased 40,238 shares of Johnson & Johnson (JNJ 0.09%) for an estimated $6.89 million during the quarter ended September 30, 2025, according to its October 10, 2025 SEC filing.",fool.com,https://www.fool.com/coverage/filings/2025/10/13/big-money-move-investment-manager-buys-usd6-9-million-worth-of-johnson-and-johnson-shares-according-to-recent-filing/,https://images.financialmodelingprep.com/news/big-money-move-investment-manager-buys-69-million-worth-20251013.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 06:20:00,2025-10-14T06:20:00-04:00,2025-10-14,Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. “Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vis.",businesswire.com,https://www.businesswire.com/news/home/20251013198483/en/Johnson-Johnson-Reports-Q3-2025-Results-Raises-2025-Sales-Outlook/,https://images.financialmodelingprep.com/news/johnson-johnson-reports-q3-2025-results-raises-2025-sales-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 06:20:00,2025-10-14T06:20:00-04:00,2025-10-14,Johnson & Johnson said Tuesday it plans to separate its artificial hip and knee business into a stand-alone company to be called DePuy Synthes,The planned separation is the latest move by J&J to slim down in recent years and focus on faster-growing businesses.,wsj.com,https://www.wsj.com/health/healthcare/johnson-johnson-to-split-off-orthopedics-business-2b9f3d62,https://images.financialmodelingprep.com/news/johnson-johnson-said-tuesday-it-plans-to-separate-its-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 06:21:00,2025-10-14T06:21:00-04:00,2025-10-14,Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an innovation powerhouse, serving areas of high unmet needs across Innovative Medicine and MedTech, accelerating the ongoing shift of the Company's MedT.",businesswire.com,https://www.businesswire.com/news/home/20251014819650/en/Johnson-Johnson-Announces-Intent-to-Separate-Its-Orthopaedics-Business/,https://images.financialmodelingprep.com/news/johnson-johnson-announces-intent-to-separate-its-orthopaedics-business-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 06:26:36,2025-10-14T06:26:36-04:00,2025-10-14,"J&J to spin off orthopedics business, raises full-year forecast","Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 2023.",reuters.com,https://www.reuters.com/legal/litigation/jj-spin-off-orthopedics-business-raises-full-year-forecast-2025-10-14/,https://images.financialmodelingprep.com/news/jj-to-spin-off-orthopedics-business-raises-fullyear-forecast-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 06:30:00,2025-10-14T06:30:00-04:00,2025-10-14,Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Q4 dividend.",businesswire.com,https://www.businesswire.com/news/home/20251014059893/en/Johnson-Johnson-Announces-Quarterly-Dividend-for-Fourth-Quarter-2025/,https://images.financialmodelingprep.com/news/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2025-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 06:32:00,2025-10-14T06:32:00-04:00,2025-10-14,"J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains",Johnson & Johnson raised its full-year sales outlook as it posted gains in both its prescription-drug and medical-device businesses in the latest quarter.,wsj.com,https://www.wsj.com/business/earnings/j-j-lifts-full-year-sales-outlook-fueled-by-pharma-med-device-gains-ef200967,https://images.financialmodelingprep.com/news/jj-lifts-fullyear-sales-outlook-fueled-by-pharma-meddevice-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 07:33:04,2025-10-14T07:33:04-04:00,2025-10-14,J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth,"Johnson & Johnson chairman and CEO Joaquin Duato joins 'Squawk Box' to discuss the company's quarterly earnings results, adding warning labels to its multiple myeloma treatment Carvykti, the decision to spin off its orthopedics business, state of the company talc lawsuits, and more.",youtube.com,https://www.youtube.com/watch?v=r6gcsWarFMU,https://images.financialmodelingprep.com/news/jj-ceo-joaquin-duato-on-q3-results-we-are-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 07:44:00,2025-10-14T07:44:00-04:00,2025-10-14,Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff,Johnson & Johnson's stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate its orthopedics business.,marketwatch.com,https://www.marketwatch.com/story/johnson-johnsons-stock-heads-for-a-record-after-a-profit-beat-and-plans-for-another-spinoff-af403f00,https://images.financialmodelingprep.com/news/johnson-johnsons-stock-heads-for-a-record-after-a-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 08:31:07,2025-10-14T08:31:07-04:00,2025-10-14,Johnson & Johnson (JNJ) Beats Q3 Earnings and Revenue Estimates,"Johnson & Johnson (JNJ) came out with quarterly earnings of $2.8 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.42 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2768049/johnson-johnson-jnj-beats-q3-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2768049,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-beats-q3-earnings-and-revenue-estimates-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 08:51:28,2025-10-14T08:51:28-04:00,2025-10-14,"Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook","Johnson & Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.",benzinga.com,https://www.benzinga.com/markets/earnings/25/10/48196108/johnson-johnson-to-separate-orthopedics-business-boosts-annual-sales-outlook,https://images.financialmodelingprep.com/news/johnson-johnson-to-separate-orthopedics-business-boosts-annual-sales-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 08:56:48,2025-10-14T08:56:48-04:00,2025-10-14,Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast,"Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings and revealed plans to spin off its orthopedics business into a standalone company, its second major separation in two years. The New Jersey-based healthcare conglomerate said it now expects product revenue between $93.5 billion and $93.",invezz.com,https://invezz.com/news/2025/10/14/johnson-johnson-to-spin-off-orthopedics-unit-after-raising-2025-sales-forecast/,https://images.financialmodelingprep.com/news/johnson-johnson-to-spin-off-orthopedics-unit-after-raising-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 08:58:15,2025-10-14T08:58:15-04:00,2025-10-14,"Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again","Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 million, up 122.5% from Q3 2024. JNJ increased its 2025 reported sales guidance from $93.2-$93.6 billion to $93.5-$93.9 billion.",seekingalpha.com,https://seekingalpha.com/article/4829768-johnson-and-johnson-q3-earnings-surprise-icotrokinra-shines-again,https://images.financialmodelingprep.com/news/johnson-johnson-q3-earnings-surprise-icotrokinra-shines-again-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 09:54:03,2025-10-14T09:54:03-04:00,2025-10-14,"Johnson & Johnson reports Q3 beat, plans orthopaedics spin-off","Johnson & Johnson (NYSE:JNJ) posted third-quarter revenue and earnings that beat Wall Street estimates, driven by strength in its pharmaceuticals and medical devices businesses. The healthcare giant reported revenue of $23.99 billion for the quarter, up 6.8% from a year ago and slightly above analysts' expectations of $23.74 billion.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1080311,https://images.financialmodelingprep.com/news/johnson-johnson-reports-q3-beat-plans-orthopaedics-spinoff-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 10:01:27,2025-10-14T10:01:27-04:00,2025-10-14,"Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides","While big banks as a group posted strong earnings, Diane King Hall notes Citigroup (C) as a standout. She talks about how stronger IPO and dealmaking markets added muscle for the company.",youtube.com,https://www.youtube.com/watch?v=r7kF8RDE4-w,https://images.financialmodelingprep.com/news/citi-c-posts-strong-earnings-stuffed-crust-strengthens-dpz-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 10:05:05,2025-10-14T10:05:05-04:00,2025-10-14,Johnson & Johnson Stock Brushes Off Beat-and-Raise,"Johnson & Johnson  (NYSE:JNJ) stock is down 1.2% to trade at $188.54 at last glance, brushing off an earnings and revenue beat for the third quarter.",schaeffersresearch.com,https://www.schaeffersresearch.com/content/news/2025/10/14/johnson-johnson-stock-brushes-off-beat-and-raise,https://images.financialmodelingprep.com/news/johnson-johnson-stock-brushes-off-beatandraise-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 10:31:28,2025-10-14T10:31:28-04:00,2025-10-14,"Compared to Estimates, Johnson & Johnson (JNJ) Q3 Earnings: A Look at Key Metrics","Although the revenue and EPS for Johnson & Johnson (JNJ) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",zacks.com,https://www.zacks.com/stock/news/2768216/compared-to-estimates-johnson-johnson-jnj-q3-earnings-a-look-at-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2768216,https://images.financialmodelingprep.com/news/compared-to-estimates-johnson-johnson-jnj-q3-earnings-a-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 11:25:27,2025-10-14T11:25:27-04:00,2025-10-14,3 Dividend Aristocrats to Buy that Continued to Beat the Market,"Finding top dividend stocks to invest in is one thing. Finding companies that can pay that dividend for years, and potentially decades, to come is a whole other story.",247wallst.com,https://247wallst.com/investing/2025/10/14/3-dividend-aristocrats-to-buy-that-continued-to-beat-the-market/,https://images.financialmodelingprep.com/news/3-dividend-aristocrats-to-buy-that-continued-to-beat-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 12:36:37,2025-10-14T12:36:37-04:00,2025-10-14,Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript,"Johnson & Johnson (NYSE:JNJ ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Company Participants Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wolk - Executive VP & CFO Jennifer Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Tim Schmid - Executive VP & Worldwide Chairman of MedTech John Reed - Executive Vice President of Innovative Medicine, R&D Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Danielle Antalffy - UBS Investment Bank, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Terence Flynn - Morgan Stanley, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Matthew Miksic - Barclays Bank PLC, Research Division David Risinger - Leerink Partners LLC, Research Division Presentation Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded.",seekingalpha.com,https://seekingalpha.com/article/4829833-johnson-and-johnson-jnj-q3-2025-earnings-call-transcript,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q3-2025-earnings-call-transcript-20251014.png
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 12:47:35,2025-10-14T12:47:35-04:00,2025-10-14,Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?,"Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?",zacks.com,https://www.zacks.com/stock/news/2768515/johnson-johnson-jnj-is-a-top-dividend-stock-right-now-should-you-buy?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_5-2768515,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-is-a-top-dividend-stock-right-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 13:01:36,2025-10-14T13:01:36-04:00,2025-10-14,"JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit","J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.",zacks.com,https://www.zacks.com/stock/news/2768552/jnj-beats-on-q3-earnings-ups-sales-view-to-spin-off-orthopaedics-unit?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2768552,https://images.financialmodelingprep.com/news/jnj-beats-on-q3-earnings-ups-sales-view-to-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-14 19:30:08,2025-10-14T19:30:08-04:00,2025-10-14,'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations,"Johnson & Johnson CFO and Executive Vice President Joe Wolk addresses the decision to spin off its orthopedics business, explains its innovations and more on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #johnsonandjohnson #joewolk #innovation #healthcare #business #pharma #medical #biotech #technology #orthopedics #science #research #corporate #leadership #economy #growth #investment #health #companynews",youtube.com,https://www.youtube.com/watch?v=QS0a_7lx3-w,https://images.financialmodelingprep.com/news/never-been-stronger-johnson-johnson-leader-touts-latest-innovations-20251014.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 05:20:00,2025-10-15T05:20:00-04:00,2025-10-15,This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy,Johnson & Johnson (JNJ -0.02%) is one of the world's best dividend stocks. The healthcare giant has increased its dividend payment for 63 consecutive years.,fool.com,https://www.fool.com/investing/2025/10/15/this-27-yielding-dividend-king-remains-one-of-the/,https://images.financialmodelingprep.com/news/this-27yielding-dividend-king-remains-one-of-the-healthiest-20251015.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 07:51:03,2025-10-15T07:51:03-04:00,2025-10-15,Johnson & Johnson reveals 2025 sales forecast and plans for its orthopedics business,"Johnson & Johnson on Tuesday raised its 2025 sales forecast after reporting quarterly earnings that topped Wall Street expectations, and announced plans to spin off its orthopedics business into a standalone company.",fastcompany.com,https://www.fastcompany.com/91421757/johnson-johnson-reveals-2025-sales-forecast-plans-orthopedics-business,https://images.financialmodelingprep.com/news/johnson-johnson-reveals-2025-sales-forecast-and-plans-for-20251015.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 08:45:00,2025-10-15T08:45:00-04:00,2025-10-15,"Johnson & Johnson’s MedTech spin-off could boost focus, Bank of America says",Bank of America maintained a ‘Neutral’ rating on Johnson & Johnson (NYSE:JNJ) after the company posted third-quarter results slightly above expectations and...,proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1080418/johnson-johnson-s-medtech-spin-off-could-boost-focus-bank-of-america-says-1080418.html,https://images.financialmodelingprep.com/news/johnson-johnsons-medtech-spinoff-could-boost-focus-bank-of-america-20251015.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 12:16:27,2025-10-15T12:16:27-04:00,2025-10-15,Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off,"Johnson & Johnson's NYSE: JNJ stock price can continue to advance because its strategy to reinvigorate growth and widen margins is working. The plan centers on divesting underperforming healthcare businesses to focus on higher-margin, more potent growth markets.",marketbeat.com,https://www.marketbeat.com/stock-ideas/johnson-and-johnson-stock-can-keep-rising-as-strategy-pays-off/,https://images.financialmodelingprep.com/news/johnson-johnson-stock-can-keep-rising-as-strategy-pays-20251015.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 12:49:58,2025-10-15T12:49:58-04:00,2025-10-15,"Johnson & Johnson's MedTech spin-off could boost focus, Bank of America says","Bank of America maintained a ‘Neutral' rating on Johnson & Johnson (NYSE:JNJ) after the company posted third-quarter results slightly above expectations and hinted at a strategic MedTech shake-up. In a note Wednesday, the bank highlighted that J&J's third-quarter revenue and earnings per share beat consensus by roughly 1%, driven largely by stronger-than-expected performance from its Stelara biologic.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1080418,https://images.financialmodelingprep.com/news/johnson-johnsons-medtech-spinoff-could-boost-focus-bank-of-20251015.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 13:56:28,2025-10-15T13:56:28-04:00,2025-10-15,"Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst","On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.",benzinga.com,https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48234008/johnson-johnson-rules-out-big-acquisitions-reiterates-focus-on-small-deals-analyst,https://images.financialmodelingprep.com/news/johnson-johnson-rules-out-big-acquisitions-reiterates-focus-on-20251015.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 14:04:28,2025-10-15T14:04:28-04:00,2025-10-15,These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings,Johnson & Johnson (NYSE:JNJ) on Tuesday reported better-than-expected third-quarter earnings on Tuesday.,benzinga.com,https://www.benzinga.com/news/25/10/48234237/these-analysts-boost-their-forecasts-on-johnson-johnson-after-upbeat-q3-earnings,https://images.financialmodelingprep.com/news/these-analysts-boost-their-forecasts-on-johnson-johnson-after-20251015.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 18:51:43,2025-10-15T18:51:43-04:00,2025-10-15,"Markets Mostly Up, Russell 2000 Sets New Closing High","The biggest movers on the day were the Nasdaq, +148 points or +0.66%, and the small-cap Russell 2000 +24 points, +0.97%.",zacks.com,https://www.zacks.com/stock/news/2769677/markets-mostly-up-russell-2000-sets-new-closing-high?cid=CS-STOCKNEWSAPI-FT-ahead_of_wall_street-2769677,https://images.financialmodelingprep.com/news/markets-mostly-up-russell-2000-sets-new-closing-high-20251015.webp
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-15 19:03:36,2025-10-15T19:03:36-04:00,2025-10-15,J&J faces first UK lawsuits alleging its baby powder caused cancer,"Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.",reuters.com,https://www.reuters.com/sustainability/boards-policy-regulation/jj-faces-first-uk-lawsuits-alleging-its-baby-powder-caused-cancer-2025-10-15/,https://images.financialmodelingprep.com/news/jj-faces-first-uk-lawsuits-alleging-its-baby-powder-caused-20251015.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-16 03:23:51,2025-10-16T03:23:51-04:00,2025-10-16,Johnson & Johnson faces UK lawsuit over talcum baby powder,"A group of around 3,000 people in the UK has filed a legal claim against Johnson & Johnson (NYSE:JNJ), accusing the pharmaceutical company of selling talcum-based baby powder contaminated with asbestos. The case draws on internal documents and scientific studies dating back to the 1960s, which allegedly show the company knew its product contained minerals such as tremolite and actinolite.",proactiveinvestors.co.uk,https://www.proactiveinvestors.co.uk/companies/news/1080474,https://images.financialmodelingprep.com/news/johnson-johnson-faces-uk-lawsuit-over-talcum-baby-powder-20251016.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-16 04:21:00,2025-10-16T04:21:00-04:00,2025-10-16,Johnson & Johnson faces UK lawsuit over talcum baby powder,"A group of around 3,000 people in the UK has filed a legal claim against Johnson & Johnson (NYSE:JNJ), accusing the pharmaceutical company of selling...",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1080474/johnson-johnson-faces-uk-lawsuit-over-talcum-baby-powder-1080474.html,https://images.financialmodelingprep.com/news/johnson-johnson-faces-uk-lawsuit-over-talcum-baby-powder-20251016.jpeg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-16 06:45:00,2025-10-16T06:45:00-04:00,2025-10-16,Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.,"The idea of steady money flowing in, year after year, should appeal to nearly everyone. This isn't an unrealistic dream; investing in stocks that pay reliable dividends can make it a reality.",fool.com,https://www.fool.com/investing/2025/10/16/want-decades-of-passive-income-3-stocks-to-buy-now/,https://images.financialmodelingprep.com/news/want-decades-of-passive-income-3-stocks-to-buy-now-20251016.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-16 08:00:00,2025-10-16T08:00:00-04:00,2025-10-16,TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care,"First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (IDMC) recommended unblinding the study based on statistically significant results RARITAN, N.J. , Oct. 16, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study.",prnewswire.com,https://www.prnewswire.com/news-releases/tecvayli-plus-darzalex-faspro-combination-regimen-significantly-improves-progression-free-survival-and-overall-survival-versus-standard-of-care-302585407.html,https://images.financialmodelingprep.com/news/tecvayli-plus-darzalex-faspro-combination-regimen-significantly-improves-progressionfree-survival-20251016.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-16 09:56:16,2025-10-16T09:56:16-04:00,2025-10-16,ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook,"JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.",zacks.com,https://www.zacks.com/stock/news/2769965/etfs-to-watch-post-jnj-s-q3-earnings-surprise-bullish-outlook?cid=CS-STOCKNEWSAPI-FT-etf_news_and_commentary-2769965,https://images.financialmodelingprep.com/news/etfs-to-watch-post-jnjs-q3-earnings-surprise-bullish-outlook-20251016.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-16 11:14:31,2025-10-16T11:14:31-04:00,2025-10-16,Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase,"Jamison Private Wealth Management, Inc. disclosed a purchase of Johnson & Johnson shares valued at $6,762,412 in its SEC filing for the period ended Q3 2025, submitted on October 14, 2025.",fool.com,https://www.fool.com/coverage/filings/2025/10/16/jamison-loads-up-on-johnson-and-johnson-jnj-stock-with-a-39k-share-purchase/,https://images.financialmodelingprep.com/news/jamison-loads-up-on-johnson-johnson-jnj-stock-with-a-20251016.png
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-16 14:06:11,2025-10-16T14:06:11-04:00,2025-10-16,J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan,J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.,zacks.com,https://www.zacks.com/stock/news/2770490/j-j-bets-on-medtech-growth-with-orthopaedics-unit-spin-off-plan?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2770490,https://images.financialmodelingprep.com/news/jj-bets-on-medtech-growth-with-orthopaedics-unit-spinoff-20251016.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-16 17:45:39,2025-10-16T17:45:39-04:00,2025-10-16,S&P 500 Gains and Losses Today: Regional Banks Slump on Worries About Bad Loans; Data Storage Stocks Surge,"Reports of elevated loan losses from regional banks weighed on the sector, while expectations of AI-driven growth helped lift shares of companies in the data storage and memory chip businesses.",investopedia.com,https://www.investopedia.com/s-and-p-500-gains-and-losses-today-regional-banks-slump-on-worries-about-bad-loans-data-storage-stocks-surge-11831378,https://images.financialmodelingprep.com/news/sp-500-gains-and-losses-today-regional-banks-slump-on-20251016.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-17 13:15:19,2025-10-17T13:15:19-04:00,2025-10-17,"Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?","JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.",zacks.com,https://www.zacks.com/stock/news/2771349/should-you-buy-sell-or-hold-j-j-stock-after-robust-q3-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2771349,https://images.financialmodelingprep.com/news/should-you-buy-sell-or-hold-jj-stock-after-20251017.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-18 12:04:51,2025-10-18T12:04:51-04:00,2025-10-18,Johnson & Johnson's M&A Strategy Is the Real Story for Investors,"Recent market speculation linking Johnson & Johnson NYSE: JNJ to a complete acquisition of its partner, Protagonist Therapeutics NASDAQ: PTGX, offers a valuable glimpse into a core corporate strategy. For a healthcare sector giant of Johnson & Johnson's scale, such moves are not about chasing short-term stock pops.",marketbeat.com,https://www.marketbeat.com/stock-ideas/johnson-and-johnsons-m-and-a-strategy-is-the-real-story-for-investors/,https://images.financialmodelingprep.com/news/johnson-johnsons-ma-strategy-is-the-real-story-for-investors-20251018.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-19 10:30:00,2025-10-19T10:30:00-04:00,2025-10-19,Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer,"Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors RARITAN, N.J. , Oct. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after disease progression on a checkpoint inhibitor and platinum-based chemotherapy.",prnewswire.com,https://www.prnewswire.com/news-releases/subcutaneous-amivantamab-delivers-promising-45-percent-overall-response-rate-with-median-duration-of-7-2-months-in-recurrent-or-metastatic-head-and-neck-cancer-302588232.html,https://images.financialmodelingprep.com/news/subcutaneous-amivantamab-delivers-promising-45-percent-overall-response-rate-20251019.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-20 11:16:43,2025-10-20T11:16:43-04:00,2025-10-20,Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys,"Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.",247wallst.com,https://247wallst.com/investing/2025/10/20/goldman-sachs-reveals-sectors-with-top-2026-payouts-grab-5-strong-buys-now/,https://images.financialmodelingprep.com/news/goldman-sachs-reveals-sectors-with-top-2026-payouts-5-strong-20251020.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-21 10:17:01,2025-10-21T10:17:01-04:00,2025-10-21,Johnson & Johnson Targets Accelerated Growth Across Segments in 2026,"J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.",zacks.com,https://www.zacks.com/stock/news/2772950/johnson-johnson-targets-accelerated-growth-across-segments-in-2026?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2772950,https://images.financialmodelingprep.com/news/johnson-johnson-targets-accelerated-growth-across-segments-in-2026-20251021.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-21 16:49:22,2025-10-21T16:49:22-04:00,2025-10-21,Johnson & Johnson Draws Long-Term Buyers as Markets Turn Cautious,"Added 91,615 shares in Johnson & Johnson; estimated transaction value of ~$15.70 million Trade represents an increase of 2.13% of the fund's reportable U.S. equity AUM Post-trade stake: 102,375 shares valued at $18.98 million as of September 30, 2025 Johnson & Johnson now accounts for 2.58% of CADINHA & CO LLC's reportable equity AUM, placing it outside the fund's top five holdings",fool.com,https://www.fool.com/coverage/filings/2025/10/21/johnson-and-johnson-draws-long-term-buyers-as-markets-turn-cautious/,https://images.financialmodelingprep.com/news/johnson-johnson-draws-longterm-buyers-as-markets-turn-cautious-20251021.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-22 10:00:23,2025-10-22T10:00:23-04:00,2025-10-22,Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know,"Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",zacks.com,https://www.zacks.com/stock/news/2773885/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2773885,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-is-attracting-investor-attention-here-is-20251022.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-22 14:00:09,2025-10-22T14:00:09-04:00,2025-10-22,Johnson & Johnson Stock To $134?,"Our machine-driven multifactor analysis suggests it may be time to sell JNJ stock, as we hold a pessimistic outlook with a potential target price of $134. The company's Moderate operating performance and financial health, combined with its High valuation, make the stock appear Unattractive.",forbes.com,https://www.forbes.com/sites/greatspeculations/2025/10/22/johnson--johnson-stock-to-134/,https://images.financialmodelingprep.com/news/johnson-johnson-stock-to-134-20251022.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-22 16:36:00,2025-10-22T16:36:00-04:00,2025-10-22,Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17th, 2025. Management will participate in a Fireside Chat at 10:40 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be availa.",businesswire.com,https://www.businesswire.com/news/home/20251022905443/en/Johnson-Johnson-to-Participate-in-the-7th-Annual-Wolfe-Research-Healthcare-Conference/,https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-7th-annual-wolfe-20251022.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-23 11:26:57,2025-10-23T11:26:57-04:00,2025-10-23,I have invested in dividends for 20 years. These stocks are my top dividend compounders of all time,"In the world of investing, dividends have long been a popular way to earn income alongside growth opportunities with stocks.",247wallst.com,https://247wallst.com/investing/2025/10/23/i-have-invested-in-dividends-for-20-years-these-stocks-are-my-top-dividend-compounders-of-all-time/,https://images.financialmodelingprep.com/news/i-have-invested-in-dividends-for-20-years-these-20251023.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-24 04:30:00,2025-10-24T04:30:00-04:00,2025-10-24,Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning,We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron in our view has a strong balance sheet and a robust product pipeline.,seekingalpha.com,https://seekingalpha.com/article/4832973-smart-acquisitions-profit-margin-growth-amid-strategic-repositioning,https://images.financialmodelingprep.com/news/smart-acquisitions-and-profit-margin-growth-amid-strategic-repositioning-20251024.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-24 08:00:00,2025-10-24T08:00:00-04:00,2025-10-24,Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis,"In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ICONIC-TOTAL study 67% of patients treated with icotrokinra achieved overall rates of clear or almost clear skin by Week 24, which was maintained through Week 52 Icotrokinra continues to show potential with its standout combination of exceptional skin clearance and favorable safety profile in a once daily pill SPRING HOUSE, Pa. , Oct. 24, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescents) with plaque psoriasis (PsO) affecting high-impact sites.",prnewswire.com,https://www.prnewswire.com/news-releases/icotrokinra-long-term-results-affirm-promise-of-targeted-oral-peptide-with-high-rates-of-durable-skin-clearance-and-favorable-safety-profile-in-difficult-to-treat-scalp-and-genital-psoriasis-302593288.html,https://images.financialmodelingprep.com/news/icotrokinra-longterm-results-affirm-promise-of-targeted-oral-peptide-20251024.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-24 11:29:19,2025-10-24T11:29:19-04:00,2025-10-24,I have invested in dividends for 25 years—These stocks prove long-term dividend investing works,"McDonald's (MCD), Johnson & Johnson (JNJ), and Walmart (WMT) have lengthy histories of dividend growth. Sticking to a dividend reinvestment plan with these three stocks yielded amazing results over the long term.",247wallst.com,https://247wallst.com/investing/2025/10/24/i-have-invested-in-dividends-for-25-years-these-stocks-prove-long-term-dividend-investing-works/,https://images.financialmodelingprep.com/news/i-have-invested-in-dividends-for-25-yearsthese-stocks-prove-20251024.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-24 18:32:00,2025-10-24T18:32:00-04:00,2025-10-24,Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies,"Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus placebo Critical patient-reported SjD symptoms including dryness, pain and fatigue trended towards greater improvement in the nipocalimab-treated group compared to placebo-treated patients Nipocalimab is the only investigational treatment to be granted Breakthrough Therapy Designation (BTD) by U.S. FDA for the treatment of adults living with moderate-to-severe SjD, and the Phase 3 DAFFODIL study is currently enrolling patients SPRING HOUSE, Pa. , Oct. 24, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly decreased disease activity and severity in patients with moderate-to-severe disease.1 The study met its primary endpoint, with statistically significant improvement in ClinESSDAI a score, a key SjD activity index, at Week 24 in the nipocalimab 15 mg/kg Q2W group compared to placebob.1 Reductions in disease activity were supported by favorable changes in key biomarkers when compared to placebo, including lower levels of rheumatoid factor, fewer circulating immune complexes, and decreased inflammatory markers.1 This significant reduction in disease activity suggests nipocalimab may lessen the burden of SjD symptoms for patients impacted by the condition.1 Patients who received nipocalimab reported a decrease in symptoms, with numerical improvements compared with placebo in the hallmark symptoms of SjD including dryness of the mouth, eyes, and/or vagina, as well as fatigue and joint pain.1 Additionally, an improvement in objective salivary flow (i.e.",prnewswire.com,https://www.prnewswire.com/news-releases/published-in-the-lancet-nipocalimab-significantly-decreased-sjogrens-disease-sjd-activity-and-severity-through-substantial-reduction-in-sjogrens-related-autoantibodies-302594367.html,https://images.financialmodelingprep.com/news/published-in-the-lancet-nipocalimab-significantly-decreased-sjgrens-disease-20251024.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-27 07:30:00,2025-10-27T07:30:00-04:00,2025-10-27,"TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years","Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only IL-23 inhibitor to demonstrate durable endoscopic and clinical remission with a fully subcutaneous regimen in moderately to severely active Crohn's disease PHOENIX , Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA ® (guselkumab) in adults with moderately to severely active Crohn's disease (CD) at two years.1 These findings are among 23 Johnson & Johnson abstracts being presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG). TREMFYA® is the first and only approved, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.",prnewswire.com,https://www.prnewswire.com/news-releases/tremfya-guselkumab-the-first-and-only-il-23-inhibitor-with-a-fully-subcutaneous-treatment-regimen-demonstrates-durable-remission-in-crohns-disease-at-two-years-302594372.html,https://images.financialmodelingprep.com/news/tremfya-guselkumab-the-first-and-only-il23-inhibitor-with-20251027.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-27 07:30:00,2025-10-27T07:30:00-04:00,2025-10-27,Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis,"Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo in the Phase 2b ANTHEM-UC study Results support Phase 3 clinical development of icotrokinra, a first-in-class targeted oral peptide that precisely blocks the IL-23 receptor, in both moderately to severely active ulcerative colitis and Crohn's disease PHOENIX , Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). These results underscore the potential of icotrokinra to deliver a combination of therapeutic benefit and a favorable safety profile with once-daily oral dosing and will be featured among Johnson & Johnson's 23 accepted abstracts at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG).",prnewswire.com,https://www.prnewswire.com/news-releases/icotrokinra-maintains-standout-combination-of-therapeutic-benefit-and-a-favorable-safety-profile-in-once-daily-pill-through-28-weeks-in-ulcerative-colitis-302594371.html,https://images.financialmodelingprep.com/news/icotrokinra-maintains-standout-combination-of-therapeutic-benefit-and-a-favorable-20251027.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-27 08:00:00,2025-10-27T08:00:00-04:00,2025-10-27,"New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile","Findings highlight opportunity for shared decision-making to improve treatment planning, with more than 90% of patients currently on injectables willing to switch to a new oral therapy with equivalent efficacy and a favorable safety profile Results show 50.5% of adult psoriasis patients eligible for systemic therapy and 47.5% of dermatology providers would prefer oral treatment over topicals or injectables SPRING HOUSE, Pa. , Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care.",prnewswire.com,https://www.prnewswire.com/news-releases/new-study-reveals-substantial-unmet-need-in-psoriasis-shows-strong-patient-and-provider-preference-for-highly-effective-oral-treatments-with-favorable-safety-profile-302594112.html,https://images.financialmodelingprep.com/news/new-study-reveals-substantial-unmet-need-in-psoriasis-shows-strong-20251027.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-27 10:21:11,2025-10-27T10:21:11-04:00,2025-10-27,JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?,"J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.",zacks.com,https://www.zacks.com/stock/news/2777669/jnj-vs-mrk-which-blue-chip-pharma-stock-should-be-in-your-portfolio?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2777669,https://images.financialmodelingprep.com/news/jnj-vs-mrk-which-bluechip-pharma-stock-should-be-in-20251027.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-27 10:50:25,2025-10-27T10:50:25-04:00,2025-10-27,Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock,"Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",zacks.com,https://www.zacks.com/stock/news/2777834/here-s-why-johnson-johnson-jnj-is-a-strong-momentum-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_momentum_score-2777834,https://images.financialmodelingprep.com/news/heres-why-johnson-johnson-jnj-is-a-strong-momentum-20251027.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-28 09:13:00,2025-10-28T09:13:00-04:00,2025-10-28,"Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks","The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit hyperactivity disorder.",reuters.com,https://www.reuters.com/world/texas-sues-jj-kenvue-claiming-they-hid-tylenols-autism-risks-2025-10-28/,https://images.financialmodelingprep.com/news/texas-sues-jj-and-kenvue-claiming-they-hid-tylenols-20251028.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-28 09:25:03,2025-10-28T09:25:03-04:00,2025-10-28,J&J Stock Can Fall,Johnson & Johnson (JNJ) is currently encountering challenges. Even the largest corporations are not invulnerable.,forbes.com,https://www.forbes.com/sites/greatspeculations/2025/10/28/jj-stock-can-fall/,https://images.financialmodelingprep.com/news/jj-stock-can-fall-20251028.jpg
JNJ,2025-10-14,2025-10-07,2025-10-28,JNJ,,2025-10-28 18:15:00,2025-10-28T18:15:00-04:00,2025-10-28,Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson,"FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- A jury today awarded $20 million to the family of Dr. Alberto A.",globenewswire.com,https://www.globenewswire.com/news-release/2025/10/28/3176059/7663/en/Levin-Papantonio-Announces-Jury-Awards-20-Million-Verdict-in-Talc-Mesothelioma-Case-Casaretto-Estate-v-Johnson-Johnson.html,https://images.financialmodelingprep.com/news/levin-papantonio-announces-jury-awards-20-million-verdict-in-20251028.jpg
